First Safety and Performance Evaluation of T45K, a Self-Assembling Peptide Barrier Hemostatic Device, After Skin Lesion Excision

George Rahmani, Jayne Prats, Terrence Norchi, Steven Kates, Veronica McInerney, Jack Woods, Jack Kelly, George Rahmani, Jayne Prats, Terrence Norchi, Steven Kates, Veronica McInerney, Jack Woods, Jack Kelly

Abstract

Background: The self-assembling peptide barrier T45K (SAPB-T45K) is an oligopeptide that rapidly forms a biocompatible hemostatic barrier when applied to wounds.

Objective: Evaluate safety and performance of SAPB-T45K in cutaneous surgery.

Materials and methods: In this single-blind study, after sequential shave excision of 2 lesions, wounds were randomized (intrapatient) to SAPB-T45K or control treatment. Safety was assessed at treatment, Day 7, and Day 30. Performance was evaluated using time to hemostasis (TTH) and ASEPSIS wound scores, with a subgroup analysis for patients with or without antiplatelet therapy.

Results: Each of 46 patients (10 [22%] with antiplatelet therapy) received randomized SAPB-T45K or control treatment for 2 wounds. Safety assessments were similar, and ASEPSIS scores reflected normal healing in both wound groups. SAPB-T45K demonstrated significantly faster median TTH (24.5 [range, 7-165] seconds) compared with control (44 [10-387] seconds), for a 41% median TTH reduction (18 [95% confidence interval, 7-35] seconds, p < .001). SAPB-T45K provided an identical median TTH of 24 seconds, regardless of antiplatelet therapy. Control median TTH was 90 and 40 seconds for patients taking or not taking antiplatelet therapy, respectively.

Conclusions: SAPB-T45K provided significantly faster median TTH versus control, especially with antiplatelet therapy, and safety profiles were similar.

Figures

Figure 1.
Figure 1.
Appearance of gelled SAPB-T45K after contact with charged surface.
Figure 2.
Figure 2.
Cryo–scanning electron micrograph (SEM) of self-assembled nanofiber network. SAPB-T45K was freshly prepared with deionized water and thoroughly mixed to obtain a clear solution, which was further diluted 1:1 in phosphate buffered saline. The sample (30 µL) was kept at room temperature for 4 hours and then flash-frozen with liquid nitrogen before loading in the cryo-SEM sample holder. The cryo-SEM instrument was cooled to −190°C. Water was sublimed from the sample at −80°C for 2 hours, then the sample was platinum coated for 15 seconds before examination. Spherical objects are artifacts, not SAPB-T45K.
Figure 3.
Figure 3.
Study schematic.
Figure 4.
Figure 4.
Representative SAPB-T45K- and control-treated wounds from 1 patient: (1) SAPB-T45K-treated (right mid-back, 1.5 cm2) and (2) control-treated wounds (left lower back, 2.0 cm2) at the time of treatment (A), Day 7 (B), and Day 30 (C).

References

    1. Totoraitis K, Cohen JL, Friedman A. Topical approaches to improve surgical outcomes and wound healing: a review of efficacy and safety. J Drugs Dermatol 2017;16:209–212.
    1. Bunick CG, Aasii SZ. Hemorrhagic complications in dermatologic surgery. Dermatol Ther 2011;24:537–550.
    1. Henley J, Brewer JD. Newer hemostatic agents used in the practice of dermatologic surgery. Dermatol Res Pract 2013;2013:279–89.
    1. Kaur RR, Glick JB, Siegel D. Achieving hemostasis in dermatology—part 1: preoperative, intraoperative, and postoperative management. Indian Dermatol Online J 2013;4:71–81.
    1. Brown DG, Wilkerson EC, Love WE. A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons. J Am Acad Dermatol 2015;72:524–34.
    1. Clappers N, Brouwer MA, Verveugt FWA. Antiplatelet treatment for coronary heart disease. Heart 2007;93:258–265.
    1. Howe N, Cherpelis B. Obtaining rapid and effective hemostasis: part I. update and review of topical hemostatic agents. J Am Acad Dermatol 2013;69:659.e1–659.e17.
    1. Achneck HE, Sileshi B, Jamiolkowski RM, Albala DM, et al. A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. Ann Surg 2010;251:217–28.
    1. Mekkawy AI, El-Mokhtar MA, Nafady NA, Yousef N, et al. In vitro and in vivo evaluation of biologically synthesized silver nanoparticles for topical applications: effect of surface coating and loading into hydrogels. Int J Nanomedicine 2017;12:759–777.
    1. Ellis-Behnke R, Liang YX, Schneider GE, So KF, et al. Compositions and methods for promoting hemostasis and other physiological activities. U.S. Patent Application 20160296660. Available from: . Accessed September 13, 2017.
    1. Csukas D, Urbanics R, Moritz A, Ellis Behnke R. AC5 Surgical HemostatTM as an effective hemostatic agent in an anticoagulated rat liver punch biopsy model. Nanomedicine 2015;11:2025–2031.
    1. Arosio P, Owczarz M, Wu H, Butte A, et al. End-to-end self-assembly of RADA16-I nanofibrils in aqueous solutions. Biophys J 2012;102:1617–26.
    1. Burks S, Spotnitz W. Safety and usability of hemostats, sealants, and adhesives. AORN J 2014;100:160–176.
    1. Arch Therapeutics, Inc. Study Report 29-09-2016. Hemostatic and tissue compatibility testing of AC5 versus commercially available products in a rat model. Data on file.

Source: PubMed

3
Tilaa